公开(公告)号：EP4228655A1

公开(公告)日：2023-08-23

申请号：EP21794137.6

申请日：2021-10-14

申请人： Institut du Cerveau et de la Moelle Epiniere ,  Institut National de la Santé et de la Recherche Médicale ,  Centre national de la recherche scientifique ,  Assistance Publique Hôpitaux de Paris ,  SORBONNE UNIVERSITE ,  Université Paris-Saclay

发明人： FIGADERE, Bruno ,  RAISMAN-VOZARI, Rita ,  MICHEL, Patrick Pierre ,  FERRIE, Laurent ,  ROSE, Clémence

IPC分类号： A61K31/65 ,  A61P25/16 ,  C07C231/12 ,  C07C235/40

公开(公告)号：EP3359538B1

公开(公告)日：2020-03-25

申请号：EP16778417.2

申请日：2016-10-10

申请人： Institut du Cerveau et de la Moelle Epiniere ,  Centre National de la Recherche Scientifique (CNRS) ,  Sorbonne Université ,  Assistance Publique - Hôpitaux de Paris ,  Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Université Paris-Saclay

发明人： FIGADERE, Bruno ,  FERRIE, Laurent ,  LE DOUARON, Gael ,  RAISMAN-VOZARI, Rita ,  MICHEL, Patrick ,  SEPULVEDA, Julia

IPC分类号： C07D471/04 ,  A61K31/498 ,  A61K31/4985 ,  A61P25/16 ,  A61P25/28

公开(公告)号：EP3359538A1

公开(公告)日：2018-08-15

申请号：EP16778417.2

申请日：2016-10-10

申请人： Institut du Cerveau et de la Moelle Epiniere ,  Centre National de la Recherche Scientifique (CNRS) ,  Sorbonne Université ,  Assistance Publique - Hôpitaux de Paris ,  Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Universite Paris-Sud

发明人： FIGADERE, Bruno ,  FERRIE, Laurent ,  LE DOUARON, Gael ,  RAISMAN-VOZARI, Rita ,  MICHEL, Patrick ,  SEPULVEDA, Julia

IPC分类号： C07D471/04 ,  A61K31/498 ,  A61K31/4985 ,  A61P25/16 ,  A61P25/28

摘要： The invention relates to compounds of formula (I), particularly for the use thereof as a medicament, especially in the treatment or prevention of neurogenerative disorders. The invention also relates to the methods for producing said compounds, and to the pharmaceutical compositions containing same. La présente invention concernedes composés de formule (I) suivante: en particulier pour leur utilisation en tant que médicament, notamment dans le traitement ou la prévention de maladies neurodégénératives,ainsi que leurs procédés de préparation et les compositions pharmaceutiques les comprenant.

公开(公告)号：EP2785344A1

公开(公告)日：2014-10-08

申请号：EP12806593.5

申请日：2012-11-29

申请人： Assistance Publique Hôpitaux De Paris

发明人： KONOFAL, Eric ,  FIGADERE, Bruno

IPC分类号： A61K31/4458 ,  A61P25/00 ,  C07D211/22

CPC分类号： A61K31/4458 ,  A61K31/445 ,  C07D211/22 ,  Y02P20/55

摘要： The invention relates to the treatment of attention-deficit hyperactivity disorder (ADHD) by means of alpha-phenyl (piperidin-2-yl) methanol or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative and specifically dextrophacetoperane. The invention further relates to an alpha-phenyl (piperidin-2-yl) methanol enantiomer (S, S) synthesis method and to a dextrophacetoperane synthesis method.

公开(公告)号：EP2313373A1

公开(公告)日：2011-04-27

申请号：EP09780818.2

申请日：2009-07-20

申请人： Centre National de la Recherche Scientifique (C.N.R.S)

发明人： SCHMIDT, Fanny ,  FIGADERE, Bruno ,  VOZARI, Rita, Sylvia ,  CHAMPY, Pierre, ,  FRANCK, Xavier

IPC分类号： C07D215/14 ,  C07D241/44 ,  A61K31/395 ,  A61K31/495 ,  A61P25/16 ,  A61P25/28

CPC分类号： C07D215/14 ,  C07D241/44

摘要： The present invention relates to compounds of Formula (I) below, to their pharmaceutically acceptable salts and to their isomers or mixtures of isomers: HetAr−X−CHR
1 R
2 (I) in which: - HetAr represents a group chosen from: - X represents a linear, saturated or unsaturated, hydrocarbon-based chain comprising from 8 to 22 carbon atoms, optionally interrupted by an –NH- or –NH-CO- group, - R
1 represents a hydrogen atom or an –OH, -O(C
1 -C
6 )alkyl, -OCO((C
1 -C
6 )alkyl), -OSO
2 ((C
1 -C
6 )alkyl) or –OSO
3 H group, and - R
2 represents a hydrogen atom or a (C
2 -C
6 )alkynyl, (C
2 ‑C
6 )alkenyl or (C
3 -C
6 )cycloalkyl group. The present invention also relates to a process for preparing the compounds of Formula (I), and also to the use thereof, especially in the treatment of neurodegenerative diseases.

公开(公告)号：EP2691377B1

公开(公告)日：2018-03-07

申请号：EP12713125.8

申请日：2012-03-30

申请人： Centre National de la Recherche Scientifique (C.N.R.S.) ,  Université Paris-Sud 11

发明人： FERRIE, Laurent ,  FIGADERE, Bruno ,  LE DOUARON, Gaël ,  RAISMAN-VOZARI, Rita ,  SCHMIDT, Fanny

IPC分类号： C07D241/42 ,  A61K31/498

CPC分类号： C07D241/42 ,  A61K31/498

公开(公告)号：EP2691377A1

公开(公告)日：2014-02-05

申请号：EP12713125.8

申请日：2012-03-30

申请人： Centre National de la Recherche Scientifique (CNRS) ,  Université Paris-Sud 11

发明人： FERRIE, Laurent ,  FIGADERE, Bruno ,  LE DOUARON, Gaël ,  RAISMAN-VOZARI, Rita ,  SCHMIDT, Fanny

IPC分类号： C07D241/44 ,  A61P25/00 ,  A61P25/28 ,  A61K31/498

CPC分类号： C07D241/42 ,  A61K31/498

摘要： The present invention relates to compounds of formula (I) below: for which: - X represents a hydrogen atom, a halogen atom, a group NO
2 or NH
2 , - R
0 represents H or -CH
2 -C≡CH, and - R
1 and R
2 each represent, independently of one another, a hydrogen atom; a saturated or unsaturated, linear or branched hydrocarbon-based chain comprising from 1 to 10 carbon atoms; or an optionally substituted aryl group, and also the pharmaceutically acceptable salts thereof, the stereoisomers thereof or mixtures of stereoisomers thereof in any proportion, in particular for use thereof as a medicament, in particular in the treatment or prevention of neurodegenerative diseases, and also the processes for the preparation thereof and the pharmaceutical compositions comprising same.

摘要翻译： 本发明涉及以下式（I）的化合物：其中：-X表示氢原子，卤素原子，基团NO2或NH2，-R0表示H或-CH2-C≡CH，-R1和R2 各自独立地表示氢原子; 饱和或不饱和的直链或支链烃基链，其包含1至10个碳原子; 或任选取代的芳基，以及其药学上可接受的盐，其立体异构体或其任何比例的立体异构体的混合物，特别是用作药物，特别是用于治疗或预防神经变性疾病，以及 其制备方法和包含其的药物组合物。

公开(公告)号：EP2403830A2

公开(公告)日：2012-01-11

申请号：EP10705616.0

申请日：2010-03-02

申请人： Centre National de la Recherche Scientifique (CNRS)

发明人： SCHMIDT, Fanny ,  FIGADERE, Bruno ,  RAISMAN-VOZARI, Rita ,  CHAMPY, Pierre

IPC分类号： C07D209/16 ,  A61K31/4045 ,  A61P25/28

CPC分类号： C07D209/16

摘要： The invention relates to a compound of the following formula (I), or to a pharmaceutically acceptable salt thereof or to a stereoisomer or mixture of stereoisomers at any proportions, where: X
1 is a CH
2 or C=O group; X
2 is a linear saturated or unsaturated carbohydrate chain with 8 to 24 carbon atoms; R
1 is a hydrogen atom or an OH or (C
1 -C
6 )alkoxy group such as methoxy; and R
2 is a CH
3 or CH
2 OR
3 group, with R
3 being a hydrogen atom or a (C
1 -C
6 )alkyl, CO-(C
1 -C
6 )alkyl or NH-(C
1 -C
6 )alkyl group. The invention also relates to the use of said compound as a drug, in particular for treating neurodegenerative diseases, and to a method for preparing same.

公开(公告)号：EP1351940B1

公开(公告)日：2007-07-25

申请号：EP02700323.5

申请日：2002-01-15

申请人： Institut de Recherche pour le Développement ( IRD) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： FAKHFAKH, Mohamed ,  FIGADERE, Bruno ,  FOURNET, Alain ,  FRANCK, Xavier ,  HOCQUEMILLER, Reynald ,  PRINA, Eric

IPC分类号： C07D215/04 ,  A61K31/47 ,  A61P33/02 ,  C07D215/02 ,  C07D215/12 ,  C07D215/24 ,  C07D405/06 ,  C07F7/08

CPC分类号： C07D215/04 ,  A61K31/47 ,  C07D215/12 ,  C07D215/14 ,  C07D215/24 ,  C07D405/06 ,  C07F7/0812 ,  Y02A50/409 ,  Y02A50/411

摘要： The invention relates to the use of quinolines having general formula (I), wherein R1 denotes H; alkyl C1-C15; alkenyl or alkynyl C2-C15; -CHO; heteroaryl; alkyl C1-C15 or alkenyl or alkynyl C2-C7 comprising at least one substituent selected from among O, halogen, -OH, -CHO, -COOH, aryloxycarbonyl, alkyloxycarbonyl C2-C8, alkenyloxycarbonyl C3-C9, nitrile, aryl, heteroaryl, arylsulphone, alkylsulphone C1-C7, thioalkyl or aminoalkyl C1-C7; alkenyl C2-C7 bearing at least one substituent selected from among NH2, alcoxy C1-C7, phenoxy, cycloalkyl C3-C6 or heteroaryloxy; alkenyl or alkynyl C2-C15 comprising at least one trialkylsilyl C1-C7; R2, in position 3, 6 or 8, denotes H; halogen; -OH; -CHO; -COOH; alkyl or alcoxy C1-C7; -NH2; alkenyl C2-C7; or alkynyl C2-C10; R1 and R2 do not both denote H. The invention is used for the preparation of a medicine to treat protozoan and retrovirus co-infections.